Bhutani, Manisha
Foureau, David M.
Atrash, Shebli http://orcid.org/0000-0003-4547-7534
Voorhees, Peter M.
Usmani, Saad Z.
Article History
Received: 9 April 2019
Revised: 31 July 2019
Accepted: 12 August 2019
First Online: 27 November 2019
Compliance with ethical standards
:
: MB has received speaker’s fees from Amgen. DMF has no conflict of interest. SA has received consulting fees from Takeda, Amgen and Celgene, and speaker’s fees from Takeda and Celgene. PMV has received consulting fees from Amgen, BMS, Celgene, Janssen, Novartis, Oncopeptides, Takeda and TeneoBio. SZU has received consulting fees from Abbvie, Amgen, BMS, Celgene, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics, Skyline Dx, Takeda and TeneoBio, and research funding from Amgen, Array Biopharma, BMS, Celgene, Janssen, Pharmacyclics, Prothena, Sanofi, Seattle Genetics, Skyline Dx and Takeda.